Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
_256_384.jpg)
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
Successes under Ayushman Bharat Digital Health Mission and Pradhan Mantri National Dialysis Programme highlighted
Subscribe To Our Newsletter & Stay Updated
